Compare Boston Scientific Corporation (BSX) vs VanEck Gold Miners ETF (GDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs VanEck Gold Miners ETF — how do they compare? Boston Scientific Corporation trades at $51.34 (market cap $74.19B), while VanEck Gold Miners ETF trades at $90.91. The key difference: VanEck Gold Miners ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | GDX | |
|---|---|---|
Market Cap | $74.19B | — |
Sector | Health | — |
52-Week High | $108.14 | $115.84 |
52-Week Low | $42.63 | $56.60 |
Enterprise Value | $86.27B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $51.27, up 1.6% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats in 2026, with Q2 EPS of $0.86 exceeding expectations. Revenue grew to $20.07B in 2025 with a 14.4% net margin, while analyst consensus shows 86% buy ratings with a $67.21 price target. Recent insider buying by the CEO and director signals confidence despite near-term guidance challenges.
BSX presents attractive valuation with 44% upside to consensus target, supported by strong fundamentals and institutional support. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with elevated RSI levels suggesting potential near-term consolidation. The long-term growth trajectory remains intact with 2026 revenue projected at $21B and 17.5% margins.
GDX, the VanEck Gold Miners ETF, trades at $91.15, up 0.73% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights institutional repositioning and strong gold price momentum driving miner performance. The ETF provides diversified exposure to gold mining equities amid a seven-week gold rally near $4,300 per ounce.
Outlook is positive given gold's strength, but risks include volatility from Fed policy shifts and miner underperformance versus bullion. Analyst sentiment is mixed, with some advocating for value while others caution on stretched valuations. Upside depends on sustained gold prices and mining operational efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →
